| Takeda Pharmaceutical Ltd ADR (TAK) | |||
|---|---|---|---|
| 13.37 0.1 (0.75%) | 05-03 16:00 | ||
| Open: | 13.34 | Pre. Close: | 13.27 |
| High: | 13.41 | Low: | 13.3 |
| Volume: | 1,333,950 | Market Cap: | 41,953(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 15.75  One year: 16.10 |
| Support: | Support1: 13.01 Support2: 10.82 |
| Resistance: | Resistance1: 13.48 Resistance2: 13.78 |
| Pivot: | 13.21 |
| Moving Averages: | MA(5): 13.22  MA(20): 13.30 MA(100): 14.17 MA(250): 14.82 |
| MACD: | MACD(12,26): -0.19 Signal(12,26,9): -0.24 |
| %K %D: | %K(14,3): 56.32 %D(3): 36.47 |
| RSI: | RSI(14): 46.70 |
| 52-Week: | High: 17.11 Low: 13.01 Change(%): -20.7 |
| Average Vol(K): | 3-Month: 1630 10-Days: 1295 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 13.426 - 13.478 | 13.478 - 13.529 |
| Low: | 13.162 - 13.225 | 13.225 - 13.288 |
| Close: | 13.269 - 13.365 | 13.365 - 13.461 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TAK ] has closed below upper band by 10.6%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - Specialty & Generic | |
| Shares Out. (M) | |
| Shares Float (M) | 3140.00 |
| % Held by Insiders | 1550000000.00 |
| % Held by Institutions | |
| Shares Short (K) | 6260 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | 0.360 |
| Book Value (p.s.) | 4.000 |
| Profit Margin | 4.28 |
| Operating Margin | 9.44 |
| Return on Assets (ttm) | 2.6 |
| Return on Equity (ttm) | 2.8 |
| Qtrly Rev. Growth | 1.3 |
| Gross Profit (p.s.) | |
| Sales Per Share | 7.722 |
| EBITDA (p.s.) | 2.241 |
| Qtrly Earnings Growth | -12.10 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | 731450.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 37.14 |
| PEG Ratio | |
| Price to Book value | 3.34 |
| Price to Sales | 1.73 |
| Price to Cash Flow | 0.02 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 8120000.000 |
